GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company’s h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.
